Blood Banking & Tissue Typing Facilities in the US: Market Size, Businesses & Forecast 2026

The Blood Banking & Tissue Typing Facilities industry in the US encompasses establishments dedicated to the collection, characterization, storage, and distribution of human blood, blood components, organs, and tissues for therapeutic use. According to the U.S. Census Bureau 2022 Economic Census, the official nationwide revenue for blood and organ banks reached $19.88 billion. Operating as a pivotal backbone of clinical healthcare, the sector is currently navigating rising demand for precision biological matching alongside systemic pressures to secure robust, volatile donor supply chains.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Blood Banking & Tissue Typing Facilities in the US industry cover?

This industry comprises standalone and regional establishments primary engaged in collecting, testing, typing, processing, storing, and distributing vital human blood, blood derivatives, and body organs or tissues. Operations rely heavily on advanced laboratory methodologies, including human leukocyte antigen (HLA) serological or molecular testing to determine histocompatibility between prospective donors and recipients. The industry's scope excludes downstream hospital-administered transfusions or dedicated direct courier services operating without short- or long-term biological storage capabilities.

• •Classified explicitly under the primary 6-digit NAICS code 621991 for institutional categorization.
• •Includes blood donor stations, blood fractionating facilities, cord blood banks, eye banks, human egg or ova banks, and regional organ donor repositories.
• •Governed commercially by processing, laboratory analysis, storage, and logistical handling fees rather than direct commodity transactions for biological material.

Who operates in the industry and how is it structured?

The market structure exhibits a dualistic composition divided between non-profit organizations and specialized for-profit entities, exhibiting notable regional concentration among its largest scale networks. Non-profit entities historically dominate the blood collection and organ procurement segments, operating alongside hospital networks to maximize regional public healthcare access. Conversely, specialized tissue processing facilities, placenta banking services, and high-frequency plasma centers more frequently operate under corporate, for-profit frameworks.

• •According to federal rulemaking disclosures, approximately 55 to 58 federally designated, non-profit Organ Procurement Organizations (OPOs) coordinate all deceased organ donation frameworks within designated US regions.
• •Non-profit entities generate the structural majority of total industry revenue, accounting for roughly 71% of aggregate sectoral turnover.
• •The market demonstrates strong concentration at the top tier, with the largest 50 organizations historically driving over 84% of combined market revenues.

What drives demand in the industry?

Sector volume is strongly responsive to macro-demographic expansions, severe trauma incidences, and the ongoing execution rate of complex surgical procedures. An aging domestic population elevates the underlying demand for surgical interventions, cancer therapies, and chronic illness treatments that heavily rely on sustained blood or tissue availability. Additionally, advancements in transplantation medicine require increasingly precise tissue typing and molecular screening, driving up testing volumes per patient interaction.

• •Accelerating demand is directly correlated with expanded clinical capacity for complex surgical categories including cardiothoracic, orthopedic, and organ transplant operations.
• •A secular uptick in systemic chronic diseases, such as advanced kidney failure or oncology cases, structurally mandates continual infusions of blood components or tissue replacements.
• •Advancing healthcare adoption metrics among elderly demographics expand the clinical baseline for major elective joint replacements requiring bone and tissue banking products.

Who are the notable companies in the industry?

The competitive landscape features dominant non-profit operators alongside publicly traded global healthcare networks that participate directly in source collection, clinical laboratory testing, or tissue engineering. Organizations compete based on the geographic density of their collection infrastructure, established relationships with hospital groups, and technical typing accuracy. Because buying and selling organs is strictly illegal under federal law, competitive positioning focuses heavily on maximizing logistically efficient processing, transportation safety, and high-purity biological yields.

• •American Red Cross operates as a premier non-profit supplier, responsible for collecting and processing a massive portion of the domestic blood supply network.
• •Vitalant and OneBlood Inc occupy substantial market shares as major, multi-regional non-profit blood service providers across numerous US states.
• •Laboratory Corporation of America Holdings (Labcorp) delivers critical, high-volume centralized HLA tissue typing and histocompatibility testing services.
• •Quest Diagnostics Incorporated serves as another major publicly listed entity offering advanced clinical laboratory pathology and biological testing services to supporting facilities.

What are the recent trends and outlook?

The industry is adapting to persistent volatility in structural volunteer donor turnout by automating collection sites and investing in digital engagement channels. Concurrently, operators are expanding capital expenditure on advanced molecular testing platforms, such as Next-Generation Sequencing (NGS), to minimize biological typing errors and improve transplant safety profiles. The logistical footprint of the industry is also standardizing around ultra-cold chain shipping frameworks to preserve cellular products over wider geographical corridors.

• •Firms are actively mitigating persistent donor shortages by leveraging algorithmic logistics models to optimize real-time routing of regional blood surpluses.
• •Investment is shifting rapidly toward automated blood processing equipment that isolates specific target components like platelets or plasma dynamically at collection points.
• •The clinical reliance on traditional whole-blood transfusions is evolving as healthcare providers favor specific, targeted component therapies to optimize utilization efficiency.

How is the industry regulated?

Facilities operate under a highly rigorous regulatory matrix overseen by multiple federal and state healthcare oversight agencies to preserve public health safety. The collection, storage, and processing workflows are strictly regulated to eliminate the transmission of infectious diseases and maintain biological integrity. Non-compliance with these extensive quality standards risks immediate facility closure, severe financial penalties, and the revocation of essential operating credentials.

• •The U.S. Food and Drug Administration (FDA) enforces strict current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) over all facilities.
• •The National Organ Transplant Act (NOTA) strictly prohibits the purchase or sale of human organs and tissues, restricting commercial operations purely to reasonable processing and recovery service fees.
• •The Centers for Medicare & Medicaid Services (CMS) regulates lab testing under the Clinical Laboratory Improvement Amendments (CLIA) and dictates strict Conditions for Coverage for Organ Procurement Organizations.

Government, statistical and trade sources used for this Claight analysis.

• U.S. Census Bureau 2022 Economic Census ·
• Centers for Medicare & Medicaid Services (CMS) 2026 Rulemaking Disclosures ·
• U.S. Food and Drug Administration (FDA) Regulatory Standards ·
• U.S. Bureau of Labor Statistics (BLS) 2026 Employment Data